-
M&A Activity in a Fragmented CDMO Market
While there has been a slowdown in M&A in the pharmaceutical industry, the contract services market remains highly fragmented and players large and small continue to enhance their competitiveness through inorganic growth.
PAP-Q1-18-NI-001 -
Creating Comprehensive Solutions through Laboratory Testing
Lack of effective management of the outbound distribution of clinical trial materials can negatively impact study outcomes.
PAP-Q1-18-CL-011 -
Artificial Intelligence in Biopharmaceutical Manufacturing
Artificial Intelligence (AI) has significant potential to change the healthcare industry, from the way patients receive treatments to the ways in which drugs are discovered and manufactured.
PAP-Q1-18-CL-011 -
Ensuring Confidence in Viral Vector Manufacturing
Cell and gene therapies are rapidly advancing to late-stage clinical trials and commercialization.
PAP-Q1-18-CL-012 -
Expanding U.S. Supply Options for Large-Volume Parenterals
With limited numbers of producers supplying large-volume parenterals (LVPs) to the US market, shortages can result when natural disasters or manufacturing problems interrupt production operations.
PAP-Q1-18-CL-013 -
Overcoming Challenges in the Complex Market for Clinical Trials and Clinical Logistics
Increasing complexity, evolving treatment strategies, advancing technologies, data security challenges and the growing focus on patient centricity are all impacting the way in which clinical trials are conducted.
PAP-Q1-18-CL-010 -
Facilitating Implementation and Customer Service with Offline Serialization
Even though the FDA has extended the deadline for compliance with unit serialization requirements, UPM Pharmaceuticals serialized its first commercial product in May 2017, well ahead of time.
PAP-Q1-18-CL-005 -
Driving Change in the Pharma Industry and Biotech One Relationship at a Time
Although small and medium-sized pharma and biotech companies are driving the growth of the industry, they often don’t receive the attention and assistance that are essential to their success.
PAP-Q1-18-CL-004 -
Why Business Continuity Management is Important for CDMOs
Members of the pharmaceutical industry have a responsibility to guarantee both the supply of high-quality medicines and the safety of their personnel.
PAP-Q1-18-CL-003 -
A New Landscape: M&A in the Discovery & Research Sector
The CRO market is condensing while experiencing rapid growth.
PAP-Q1-18-NI-002 -
Getting to the Finish Line
The industry’s accelerating development of biopharmaceuticals has put pressure on the supply chain to improve and modernize fill/finish operations.
PAP-Q1-18-NI-004 -
What’s Driving M&A Among Pharma Sponsors?
Companies are seeking access to new technologies, looking to expand their pipelines and therapeutic expertise and reach both new patient populations and geographies.
PAP-Q1-18-NI-003 -
Overcoming Formulation Challenges with Liquid-fill Capsules
Liquid-filled hard-shell capsules enable formulators to overcome issues with complex APIs, while also achieving improved efficacy and safety.
PAP-Q1-18-CL-004 -
Uniting the Industry for the Prevention of “Pharmageddon”
Revolutionary change is occurring in the pharmaceutical industry.
PAP-Q1-18-CL-001 -
Microbial and Biological Decontamination of Equipment Brings Peace of Mind
The ramifications of an adverse biological occurrence are higher in the pharmaceutical industry than in any other.
PAP-Q1-18-CL-002 -
Investing in New Technologies for Innovative Functional Solutions
Following a reorganization and finalization of its new growth strategy, SPI is re-engaging in innovation.
PAP-Q1-18-CL-009 -
Supporting Parenteral Development and Manufacturing with End-to-End Services
The manufacture of biologic drug products, particularly those that require aseptic processing, is quite complex and requires specialized expertise.
PAP-Q1-18-CL-014 -
Death to Cleanrooms in Biopharmaceutical Manufacturing
Recently, advances in the design, form, function and operation of bioprocessing equipment has made it possible to close — or functionally close — biological active ingredient (API) manufacturing operations.
PAP-Q1-18-CL-006 -
Meet Chemo CMO: Preferred Partner for Injectables Manufacturing
API sterilization is a unique capability, and particularly important for products formulated as suspensions.
PAP-Q1-18-CL-015 -
Fully Supporting Customer Needs for Biologics Development and Manufacturing
Over the past seven years, Samsung BioLogics has constructed three state-of-the-art production facilities offering end-to-end integrated services to support the rapidly expanding clinical and commercial needs of customers.
PAP-Q1-18-CL-016 -
Meeting the Need for Small-Volume API Manufacturing
As the pharmaceutical industry shifts its focus from blockbusters to targeted therapies, the demand for active pharmaceutical ingredient (API) manufacturing capabilities at the kilogram scale is increasing.
PAP-Q1-18-CL-016 -
Focused on Fermentation
Microbial fermentation continues to be an important upstream bioprocess for the production of conventional and next-generation biologics
PAP-Q1-18-CL-007 -
Leveraging Lyophilization Development Expertise for Clinical Manufacturing
Biopharmaceutical companies are increasingly relying on contract service providers with specialized lyophilization expertise and equipment.
PAP-Q1-18-CL-008 -
Q: What Role has M&A Played in your Company’s Growth?
How mergers and acquistions have made an impact.
PAP-Q4-17-RT-001 -
Q: How do you Address Operational Excellence as an Institution?
Planning for growth and flexibility at the operational level.
PAP-Q4-17-RT-002
-
Fully Supporting Customer Needs for Biologics Development and Manufacturing
James Park, Senior Vice President and Global Head, Business Development Center for Samsung BioLogics discusses the construction of three state-of-the-art production facilities in the last seven years.
-
Focused on Fermentation
Capua BioServices continues to invest to support modern fermentation, explains Elise Mous Director Sales & Marketing/Business Development and Thomas De Maria, Business Development Manager.
-
From Qualified to Ideal: The Importance of Partnership
Nice Insight's virtual panelists weigh in on what makes contract service relationships work best.
-
Nice Insight Overview: The Key to Pharma’s Next Generation Success
Evolving markets are prompting drug owners and developers to pursue new business models in the post-blockbuster era.
-
Supporting Parenteral Development and Manufacturing with End-to-End Services
Oskar Gold, Senior Vice President of Key Account Management and Marketing/Corporate Communications for Vetter, explains leveraging end-to-end support.
-
In Close Supplier-Partner Relationships, What Pitfalls Do You Try to Avoid? How Close is Too Close?
Experts weigh in on our Roundtable question.
-
FDA Approves New Migraine Treatment
The first-in-class injectable, Aimovig, gains approval.
-
New Single-Pill HIV Treatment Approved in Europe
Juluca from ViiV Healthcare is the first 2-drug regimen offered in a once-daily pill.
-
FDA Approves the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults
Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority.
-
LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo.
-
Expanding U.S. Supply Options for Large-Volume Parenterals
Marga Viñes, Business Development Manager, Grifols discusses the company’s vertical integration philosophy.
-
Building the Foundation of Japan’s Premier CDMO
Jun Yokohama, President & CEO of Bushu Pharmaceuticals Ltd. and Toshio Yoshioka, President at Spera Pharma, Inc. discuss how the firm helps clients overcome barriers to entry.
-
Perspectives on Product Pricing Strategy and Practice
Getting pricing “right” is a tricky balancing act, but one that offers tremendous value for all.
-
Moving Beyond Monoclonal Antibodies
Next-generation antibody therapeutics are designed to provide improved specificity, efficacy and safety when compared to conventional monoclonal antibodies.
-
Becoming Bioavailable
Poorly soluble molecules in the pipeline can have a negative effect on your active pharmaceutical ingredient (API).
-
How is the Need to Provide Local Drug-Product Supply in Multiple Regions Around the World Impacting Pharmaceutical Manufacturing Facility and Equipment Design?
Experts from across the industry lend their thoughts to the Roundtable.
-
WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang
The new biologics center will include process development labs, clinical manufacturing facility (MFG9) with 5,000 L bioreactor capacity and commercial manufacturing facility (MFG8) with 48,000 L bioreactor capacity.
-
Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA
RETACRIT, the First U.S. Biosimilar Erythropoiesis-Stimulating Agent (ESA), is now approved across all indications.
-
Cancer Immunotherapies Reach Patients More Quickly Than Other Drugs
The rapid adoption of new cancer immunotherapies raises some concerns.
-
Researchers Develop Diagnostic for Rare Cancer-Generated Glycoproteins
Engineered chemical trap detects rare glycoproteins emitted as cancer first develops.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestCancer Immunotherapies Reach Patients More Quickly Than Other Drugs
May 18, 2018 11:48:11 AM PAO-M05-18-NI-013Researchers Develop Diagnostic for Rare Cancer-Generated Glycoproteins
May 18, 2018 11:43:59 AM PAO-M05-18-NI-012Medigene, Bluebird Bio Collaboration on TCR Immunotherapy Extended
May 17, 2018 12:33:28 PM PAO-M05-18-NI-010Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review
May 15, 2018 11:30:45 AM PAO-M05-18-NI-009CRISPR Gene Editing Technology Could Eliminate the Need for Hemophilia B Sufferers to Receive Ongoing Injections
May 10, 2018 2:14:32 PM PAO-M05-18-NI-007GlobalData Predicts Strong Sales for Humira Biosimilars in Europe
May 10, 2018 2:11:16 PM PAO-M05-18-NI-006
TOPICS
View All TopicsPRESS RELEASES
View All-
WuXi Biologics and Bioasis Announce Initial Strategic Collaboration
May 23, 2018 7:00:00 AM -
Paragon Bioservices Recognized as Life Science Company of the Year by Maryland Tech Council
May 23, 2018 7:00:00 AM -
HistoIndex and CymaBay Therapeutics Team up to Advance NASH Drug Development
May 22, 2018 7:00:00 AM
Nice Insight Industry Benchmark Reports 2017
Download Sample Report
